The readiness of the spontaneous reporting system for COVID-19 vaccines safety monitoring in Croatia

1 Y. M. Mesfin, A. Cheng, J. Lawrie and J. Buttery, Use of routinely collected electronic healthcare data for postlicensure vaccine safety signal detection: a systematic review, BMJ Global Health 4(4) (2019) e001065 (14 pages); https://doi.org/10.1136/bmjgh-2018-001065 Search in Google Scholar

2 European Medicines Agency (EMA), Comirnaty: EPAR – Public Assessment Report, EMA/707383/2020, December 2020; https://www.ema.europa.eu/en/documents/assessment-report/comirnaty-epar-public-assessment-report_en.pdf; last access date September 15, 2022 Search in Google Scholar

3 European Medicines Agency (EMA), Spikevax (previously COVID-19 Vaccine Moderna): EPAR – Public Assessment Report, EMA/15689/2021, January 2021; https://www.ema.europa.eu/en/documents/assessment-report/spikevax-previously-covid-19-vaccine-moderna-epar-public-assessment-report_en.pdf; last access date September 15, 2022 Search in Google Scholar

4 European Medicines Agency (EMA), Vaxzevria (previously COVID-19 Vaccine AstraZeneca): EPAR – Public Assessment Report, EMA/94907/2021, February 2021; https://www.ema.europa.eu/en/documents/assessment-report/vaxzevria-previously-covid-19-vaccine-astrazeneca-epar-public--assessment-report_en.pdf; last access date September 15, 2022 Search in Google Scholar

5 European Medicines Agency (EMA), COVID-19 Vaccine Janssen: EPAR – Public Assessment Report, EMA/158424/2021, March 2021; https://www.ema.europa.eu/en/documents/assessment-report/covid-19-vaccine-janssen-epar-public-assessment-report_en.pdf; last access date September 15, 2022 Search in Google Scholar

6 D. Mevorach, E. Anis, N. Cedar, M. Bromberg, E. J. Haas, E. Nadir, S. Olsha-Castell, D. Arad, T. Hasin, N. Levi, R. Asleh, O. Amir, K. Meir, D. Cohen, R. Dichtiar, D. Novick, Y. Hershkovitz, R. Dagan, I. Leitersdorf, R. Ben-Ami, I. Miskin, W. Saliba, K. Muhsen, Y. Levi, M. S. Green, L. Keinan-Boker and S. Alroy-Preis, Myocarditis after BNT162b2 mRNA vaccine against Covid-19 in Israel, N. Engl. J. Med. 385(23) (2021) 2140–2149; https://doi.org/10.1056/NEJMoa2109730 Search in Google Scholar

7 Ø. Karlstad, P. Hovi, A. Husby, T. Härkänen, R. M. Selmer, N. Pihlström, J. V. Hansen, H. Nohynek, N. Gunnes, A. Sundström, J. Wohlfahrt, T. A. Nieminen, M. Grünewald, H. L. Gulseth, A. Hviid and R. Ljung, SARS-CoV-2 vaccination and myocarditis in a Nordic cohort study of 23 million residents, JAMA Cardiol. 7(6) (2022) 600–612; https://doi.org/10.1001/jamacardio.2022.0583 Search in Google Scholar

8 A. Greinacher, T. Thiele, T. E. Warkentin, K. Weisser, P. A. Kyrle and S. Eichinger, Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination, N. Engl. J. Med. 384(22) (2021) 2092–2101; https://doi.org/10.1056/NEJMoa2104840 Search in Google Scholar

9 European Medicines Agency (EMA), Guideline on Good Pharmacovigilance Practices (GVP): Module IX – Signal management, Current revision 1 version, EMA/827661/2011, October 2017; https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-gvp-module-ix-signal-management-rev-1_en.pdf; last access date January 20, 2023 Search in Google Scholar

10 H. Azarpanah, M. Farhadloo, R. Vahidov and L. Pilote, Vaccine hesitancy: evidence from an adverse events following immunization database, and the role of cognitive biases, BMC Public Health 21(1) (2021) Article ID 1686 (13 pages); https://doi.org/10.1186/s12889-021-11745-1 Search in Google Scholar

11 X. Kurz, F. Domergue, J. Slattery, A. Segec, A. Szmigiel and A. Hidalgo-Simon, Safety monitoring of Influenza A/H1N1 pandemic vaccines in EudraVigilance, Vaccine 29(26) (2011) 4378–4387; https://10.1016/j.vaccine.2011.04.005 Search in Google Scholar

12 M. Sturkenboom, P. Bahri, A. Chiucchiuini, T. Grove Krause, S. Hahné, A. Khromava, M. Kokki, P. Kramarz, X. Kurz, H. J. Larson, S. de Lusignan, P. Mahy, L. Torcel-Pagnon, L. Titievsky, V. Bauchau, Why we need more collaboration in Europe to enhance post-marketing surveillance of vaccines?, Vaccine 38 Supplement 2 (2020) B1-B7; https://doi.org/10.1016/j.vaccine.2019.07.081 Search in Google Scholar

13 European Medicines Agency (EMA), EudraVigilance, https://www.ema.europa.eu/en/human-regulatory/research-development/pharmacovigilance/eudravigilance; last access date September 16, 2022 Search in Google Scholar

14 European Medicines Agency (EMA), Guideline on Good Pharmacovigilance Practices (GVP): Module VI – Collection, Management and Submission of Reports of Suspected Adverse Reactions to Medicinal Products, Current revision 2 version, EMA/873138/2011, July 2017; https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guideline-good-pharmacovigilance-practices-gvp-module-vi-collection-management-submission-reports_en.pdf; last access date September 16, 2022 Search in Google Scholar

15 International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH), Medical Dictionary for Regulatory Activities (MedDRA), MedDRA^® Data Retrieval and Presentation: Points to Consider ICH-Endorsed Guide for Meddra Users on Data Output, Release 3.22, March 2022; https://admin.meddra.org/sites/default/files/guidance/file/000715_datretptc_r3_22_mar2022.pdf; last access date September 16, 2022 Search in Google Scholar

16 International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH), Medical Dictionary for Regulatory Activities (MedDRA), MedDRA Hierarchy, https://www.meddra.org/how-to-use/basics/hierarchy; last access on September 16, 2022 Search in Google Scholar

17 International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH), Medical Dictionary for Regulatory Activities (MedDRA), Standardised MedDRA Queries, https://www.meddra.org/standardised-meddra-queries; last access on September 16, 2022 Search in Google Scholar

18 European Medicines Agency (EMA), MedDRA Important medical event terms list, Current version 25.1, EMA/782876/2022, 26 September 2022; https://www.ema.europa.eu/en/human-regulatory/research-development/pharmacovigilance/eudravigilance/eudravigilance-system-overview; last access on February 15, 2023 Search in Google Scholar

19 K. S. Kohl, J. Bonhoeffer, M. M. Braun, R. T. Chen, P. Duclos, H. Heijbel, U. Heininger, E. Loupi, and S. M. Marcy, The Brighton Collaboration: Creating a Global Standard for Case Definitions (and Guidelines) for Adverse Events Following Immunization, in Advances in Patient Safety: From Research to Implementation, Vol. 2: Concepts and Methodology (Eds. K. Henriksen, J. B. Battles, E. S. Marks and D. I. Lewin), Agency for Healthcare Research and Quality, Rockville (MD, USA) 2005, pp. 87–102; https://www.ncbi.nlm.nih.gov/books/NBK20507/; last access on May 10, 2022 Search in Google Scholar

20 The Brighton Collaboration, Brighton Collaboration Case Definitions; https://brightoncollaboration.us/category/pubs-tools/case-definitions/; last access on May 10, 2022 Search in Google Scholar

21 J. Chapin-Bardales, J. Gee and T. Myers, Reactogenicity following receipt of mRNA-based COVID-19 vaccines, JAMA 325(21) (2021) 2201–2202; https://doi.org/10.1001/jama.2021.5374 Search in Google Scholar

22 D. K. Shay, J. Gee, J. R. Su, T. R. Myers, P. Marquez, R. Liu, B. Zhang, C. Licata, T. A. Clark and T. T. Shimabukuro, Safety monitoring of the Janssen (Johnson & Johnson) COVID-19 vaccine — United States, March–April 2021, Morb. Mortal. Wkly. Rep. 70(18) (2021) 680–684; https://www.cdc.gov/mmwr/volumes/70/wr/mm7018e2.htm Search in Google Scholar

23 M. Voysey, S. A. C. Clemens, S. A. Madhi, L. Y. Weckx, P. M. Folegatti, P. K. Aley, B. Angus, V. L. Baillie, S. L. Barnabas, Q. E. Bhorat, S. Bibi, C. Briner, P. Cicconi, A. M. Collins, R. Colin-Jones, C. L. Cutland, T. C. Darton, K. Dheda, C. J. A. Duncan, K. R. W. Emary, K. J. Ewer, L. Fairlie, S. N. Faust, S. Feng, D. M. Ferreira, A. Finn, A. L. Goodman, C. M. Green, C. A. Green, P. T. Heath, C. Hill, H. Hill, I. Hirsch, S. H. C. Hodgson, A. Izu, S. Jackson, D. Jenkin, C. C. D. Joe, S. Kerridge, A. Koen, G. Kwatra, R. Lazarus, A. M. Lawrie, A. Lelliott, V. Libri, P. J. Lillie, R. Mallory, A. V. A. Mendes, E. P. Milan, A. M. Minassian, A. McGregor, H. Morrison, Y. F. Mujadidi, A. Nana, P. J. O’Reilly, S. D. Padayachee, A. Pittella, E. Plested, K. M. Pollock, M. N. Ramasamy, S. Rhead, A. V. Schwarzbold, N. Singh, A. Smith, R. Song, M. D. Snape, E. Sprinz, R. K. Sutherland, R. Tarrant, E. C. Thomson, M. E. Török, M. Toshner, D. P. J. Turner, J. Vekemans, T. L. Villafana, M. E. E. Watson, C. J. Williams, A. D. Douglas, A. V. S. Hill, T. Lambe, S. C. Gilbert, and A. J. Pollard (Oxford COVID vaccine trial group), Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK, Lancet 397(10269) (2021) 99–111; https://doi.org/10.1016/S0140-6736(20)32661-1 Search in Google Scholar

24 K. Ali, G. Berman, H. Zhou, W. Deng, V. Faughnan, M. Coronado-Voges, B. Ding, J. Dooley, B. Girard, W. Hillebrand, R. Pajon, J. M. Miller, B. Leav and R. McPhee, Evaluation of mRNA-1273 SARS-CoV-2 vaccine in adolescents, N. Engl. J. Med. 385(24) (2021) 2241–2251; https://doi.org/10.1056/NEJMoa2109522 Search in Google Scholar

25 Y. June Choe, S. Yi, I. Hwang, J. Kim, Y. J. Park, E. Cho, M. Jo, H. Lee and E. Hwa Choi, Safety and effectiveness of BNT162b2 mRNA Covid-19 vaccine in adolescents, Vaccine 40(5) (2022) 691–694; https://doi.org/10.1016/j.vaccine.2021.12.044 Search in Google Scholar

26 G. Li, F. Cappuccini, N. G. Marchevsky, P. K. Aley, R. Aley, R. Anslow, S. Bibi, K. Cathie, E. Clutter-buck, S. N. Faust, S. Feng, P. T. Heath, S. Kerridge, A. Lelliott, Y. Mujadidi, K. F. Ng, S. Rhead, H. Roberts, H. Robinson, M. R. Roderick, N. Singh, D. Smith, M. D. Snape, R. Song, K. Tang, A. Yao, X. Liu, T. Lambe and A. J. Pollard (the COV006 study team), Safety and immunogenicity of the ChA-dOx1 nCoV-19 (AZD1222) vaccine in children aged 6-17 years: a preliminary report of COV006, a phase 2 single-blind, randomised, controlled trial, Lancet 399(10342) (2022) 2212–2225; https://doi.org/10.1016/S0140-6736(22)00770-X (erratum in: Lancet 400(10345) (2022) 24) Search in Google Scholar

27 W. Fu, B. Sivajohan, E. McClymont, A. Albert, C. Elwood, G. Ogilvie and D. Money, Systematic review of the safety, immunogenicity, and effectiveness of COVID-19 vaccines in pregnant and lactating individuals and their infants, Int. J. Gynaecol. Obstet. 156(3) (2022) 406–417; https://doi.org/10.1002/ijgo.14008 Search in Google Scholar

28 N. Luxi, A. Giovanazzi, A. Capuano, S. Crisafulli, P. M. Cutroneo, M. P. Fantini, C. Ferrajolo, U. Moretti, E. Poluzzi, E. Raschi, C. Ravaldi, C. Reno, M. Tuccori, A. Vannacci, G. Zanoni and G. Trifirò and Ilmiovaccino COVID19 collaborating group, COVID-19 vaccination in pregnancy, paediatrics, immunocompromised patients, and persons with history of allergy or prior SARS-CoV-2 infection: Overview of current recommendations and pre- and post-marketing evidence for vaccine efficacy and safety, Drug Safety 44(12) (2021) 1247–1269; https://doi.org/10.1007/s40264-021-01131-6 Search in Google Scholar

29 A. Ciapponi, A. Bardach, A. Mazzoni, T. Alconada, S. A. Anderson, F. J. Argento, J. Ballivian, K. Bok, D. Comandé, E. Erbelding, E. Goucher, B. Kampmann, R. Karron, F. M. Munoz, M. C. Palermo, E. P. K. Parker, F. Rodriguez Cairoli, V. Santa María, A. S. Stergachis, G. Voss, X. Xiong, N. Zamora, S. Zaraa, M. Berrueta and P. M. Buekens, Safety of components and platforms of COVID-19 vaccines considered for use in pregnancy: A rapid review, Vaccine 39(40) (2021) 5891–5908; https://doi.org/10.1016/j.vaccine.2021.08.034 Search in Google Scholar

30 W. A. Hauser, J. F. Annegers and L. T. Kurland, Prevalence of epilepsy in Rochester, Minnesota: 1940–1980, Epilepsia 32(4) (1991) 429–445; https://doi.org/10.1111/j.1528-1157.1991.tb04675.x Search in Google Scholar

31 E. Oka, Y. Ohtsuka, H. Yoshinaga, N. Murakami, K. Kobayashi and T. Ogino, Prevalence of childhood epilepsy and distribution of epileptic syndromes: a population-based survey in Okayama, Japan, 47(3) Epilepsia (2006) 626–630; https://doi.org/10.1111/j.1528-1167.2006.00477.x Search in Google Scholar

32 S. A. Russ, K. Larson and N. Halfon, A national profile of childhood epilepsy and seizure disorder, Pediatrics 129(2) (2012) 256–264; https://doi.org/10.1542/peds.2010-1371 Search in Google Scholar

33 K. M. Aaberg, N. Gunnes, I. J. Bakken, C. Lund Søraas, A. Berntsen, P. Magnus, M. I. Lossius, C. Stoltenberg, R. Chin and P. Surén, Incidence and prevalence of childhood epilepsy: a nationwide cohort study, Pediatrics 139(5) (2017) e20163908 (9 pages); https://doi.org/10.1542/peds.2016-3908 Search in Google Scholar

34 C. Dugas and V. H. Slane, Miscarriage, in StatPearls (updated 2022 Jun 27), StatPearls Publishing, Treasure Island (FL, USA), Internet 2022, Bookshelf ID: NBK532992 (4 pages). Search in Google Scholar

35 M. C. Magnus, A. J. Wilcox, N.-H. Morken, C. R. Weinberg and S. E. Håberg, Role of maternal age and pregnancy history in risk of miscarriage: prospective register based study, BMJ 364(8192) (2019) Article ID I869 (8 pages); https://doi.org/10.1136/bmj.l869 Search in Google Scholar

36 A. J. Wilcox, C. R. Weinberg, J. F. O’Connor, D. D. Baird, J. P. Schlatterer, R. E. Canfield, E. G. Armstrong and B. C. Nisula, Incidence of early loss of pregnancy, N. Engl. J. Med. 319(4) (1988) 189–194; https://doi.org/10.1056/NEJM198807283190401 Search in Google Scholar

37 W. Fu, B. Sivajohan, E. McClymont, A. Albert, C. Elwood, G. Ogilvie and D. Money, Systematic review of the safety, immunogenicity, and effectiveness of COVID-19 vaccines in pregnant and lactating individuals and their infants, Int. J. Gynaecol. Obstet. 156(3) (2022) 406–417; https://doi.org/10.1002/ijgo.14008 Search in Google Scholar

38 L. H. Zauche, B. Wallace, A. N. Smoots, C. K. Olson, T. Oduyebo, S. Y. Kim, E. E. Peterson, J. Ju, J. Beauregard, A. J. Wilcox, C. E. Rose, D. M. Meaney-Delman and S. R. Ellington (for the CDC v-safe Covid-19 pregnancy registry team), Receipt of mRNA Covid-19 vaccines and risk of spontaneous abortion, N. Engl. J. Med. 385(16) (2021) 1533–1535; https://doi.org/10.1056/NEJMc2113891 Search in Google Scholar

39 M. C. Magnus, H. K. Gjessing, H. N. Eide, A. J. Wilcox, D. B. Fell and S. E. Håberg, Covid-19 vacci-nation during pregnancy and first-trimester miscarriage, N. Engl. J. Med. 385(21) (2021) 2008–2010; https://doi.org/10.1056/NEJMc2114466 Search in Google Scholar

40 D. A. Salmon and N. A. Halsey, Chapter 8 - How Vaccine Safety is Monitored, in The Vaccine Book (Eds. B. R. Bloom and P.-H. Lambert), 2^nd ed., Elsevier-Academic Press, Amsterdam 2016, pp. 153–165; https://doi.org/10.1016/B978-0-12-802174-3.00008-4 Search in Google Scholar

41 A. Buoninfante, A. Andeweg, A. T. Baker, M. Borad, N. Crawford, J. M. Dogné, D. Garcia-Azorin, A. Greinacher, R. Helfand, A. Hviid, S. Kochanek, M. López-Fauqued, I. Nazy, A. Padmanabhan, S. Pavord, D. Prieto-Alhambra, H. Tran, U. Wandel Liminga and M. Cavaleri, Understanding thrombosis with thrombocytopenia syndrome after COVID-19 vaccination, npj Vaccines 7 (2022) Article ID 141 (6 pages); https://doi.org/10.1038/s41541-022-00569-8 Search in Google Scholar

42 G. Witberg, N. Barda, S. Hoss, I. Richter, M. Wiessman, Y. Aviv, T. Grinberg, O. Auster, N. Dagan, R. D. Balicer and R. Kornowski, Myocarditis after Covid-19 vaccination in a large health care organization, N. Engl. J. Med. 385(23) (2021) 2132–2139; https://doi.org/10.1056/NEJMoa2110737 Search in Google Scholar

43 S. A. Buchan, C. Yon Seo, C. Johnson, S. Alley, J. C. Kwong, S. Nasreen, A. Calzavara, D. Lu, T. M. Harris, K. Yu and S. E. Wilson, Epidemiology of myocarditis and pericarditis following mRNA vaccination by vaccine product, schedule, and interdose interval among adolescents and adults in Ontario, Canada, JAMA Netw. Open 5(6) (2022) e2218505 (12 pages); https://doi.org/10.1001/jamanetworkopen.2022.18505 Search in Google Scholar

44 European Medicines Agency (EMA), Signal Assessment Report on Myocarditis, Pericarditis with Tozinameran (COVID-19 mRNA vaccine (Nucleoside-Modified) – COMIRNATY), EPITT no: 19712, EMEA/H/C/005735/SDA/032.2, December 2021; https://www.ema.europa.eu/en/documents/pracrecom-mendation/signal-assessment-report-myocarditis-peri carditis-tozin ameran-covid-19-mrnavaccine_en.pdf; last access date September 19, 2022 Search in Google Scholar

45 European Medicines Agency (EMA), COVID-19 Vaccine Safety Update: COVID-19 VACCINE JANSSEN, October 2021; https://www.ema.europa.eu/en/documents/covid-19-vaccine-safety-update/covid-19-vaccine-safety-update-covid-19-vaccine-janssen-6-october-2021_en.pdf; last access date September 19, 2022 Search in Google Scholar

46 European Medicines Agency (EMA), COVID-19 vaccine safety update: VAXZEVRIA, November 2021; https://www.ema.europa.eu/en/documents/covid-19-vaccine-safety-update/covid-19-vaccine-safety-update-vaxzevria-previously-covid-19-vaccine-astrazeneca-11-november-2021_en.pdf; last access date January 25, 2023 Search in Google Scholar

47 L. Cari, M. Naghavi Alhosseini, P. Fiore, S. Pierno, S. Pacor, A. Bergamo, G. Sava and G. Nocentini, Cardiovascular, neurological, and pulmonary events following vaccination with the BNT162b2, ChAdOx1 nCoV-19, and Ad26.COV2.S vaccines: An analysis of European data, J. Autoimmun. 125 (2021) Article ID 102742 (17 pages); https://doi.org/10.1016/j.jaut.2021.102742 Search in Google Scholar

48 N. Barda, N. Dagan, Y. Ben-Shlomo, E. Kepten, J. Waxman, R. Ohana, M. A. Hernán, M. Lipsitch, I. Kohane, D. Netzer, B. Y. Reis and R. D. Balicer, Safety of the BNT162b2 mRNA Covid-19 vaccine in a nationwide setting, N. Engl. J. Med. 385(12) (2021) 1078–1090; https://doi.org/10.1056/nejmoa2110475 Search in Google Scholar

49 M. J. Jabagi, J. Botton, M. Bertrand, A. Weill, P. Farrington, M. Zureik and R. Dray-Spira, Myocardial infarction, stroke, and pulmonary embolism after BNT162b2 mRNA COVID-19 vaccine in people aged 75 years or older, JAMA 327(1) (2022) 80–82; https://doi.org/10.1001/jama.2021.21699 Search in Google Scholar

50 J. Hippisley-Cox, M. Patone, X. W. Mei, D. Saatci, S. Dixon, K. Khunti, F. Zaccardi, P. Watkinson, M. Shankar-Hari, J. Doidge, D. A. Harrison, S. J. Griffin, A. Sheikh and C. A. C. Coupland, Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and SARS-CoV-2 positive testing: self-controlled case series study, BMJ 374(8304) (2021) Article ID n1931 (11 pages); https://doi.org/10.1136/bmj.n1931 Search in Google Scholar

51 C. R. Simpson, T. Shi, E. Vasileiou, S. V. Katikireddi, S. Kerr, E. Moore, C. McCowan, U. Agrawal, S. A. Shah, L. D. Ritchie, J. Murray, J. Pan, D. T. Bradley, S. J. Stock, R. Wood, A. Chuter, J. Beggs, H. R. Stagg, M. Joy, R. S. M. Tsang, S. de Lusignan, R. Hobbs, R. A. Lyons, F. Torabi, S. Bedston, M. O’Leary, A. Akbari, J. McMenamin, C. Robertson and A. Sheikh, First-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland, Nat. Med. 27(7) (2021) 1290–1297; https://doi.org/10.1038/s41591-021-01408-4 Search in Google Scholar

52 A. Pottegård, L. C. Lund, Ø. Karlstad, J. Dahl, M. Andersen, J. Hallas, Ø. Lidegaard, G. Tapia, H. Løvdal Gulseth, P. Lopez-Doriga Ruiz, S. Viksmoen Watle, A. Pretzmann Mikkelsen, L. Pedersen, H. Toft Sørensen, R. Wernich Thomsen and A. Hviid, Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: Population based cohort study, BMJ 373(8293) (2021) Article ID n114 (10 pages); https://doi.org/10.1136/bmj.n1114 Search in Google Scholar